Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Mullerian hormone and body weight

Research question: How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? Design: Retrospective analysis of 153 potential high responders identified on the basis of baseline serum anti-Mullerian hormone (AMH) levels above 35 pmol/l, who were originally randomized to an individualized fixed dose of follitropin delta based on AMH and body weight (n = 78) or to a daily starting dose of 150 IU follitropin alfa (n = 75). Results: At the end of stimulation, patients treated with individualized follitropin delta or conventional follitropin alfa had 12.1 +/- 7.0 and 18.3 +/- 7.0 (P < 0.001) follicles measuring 12 mm or wider, and 27.3% and 62.7% had serum progesterone levels higher than 3.18 nmol/l (P < 0.001), respectively. Overall number of oocytes in these two respective arms was 9.3 +/- 6.7 and 17.9 +/- 8.7 (P < 0.001), and the ongoing pregnancy rate per started cycle after fresh blastocyst transfer was 28.2% and 24.0%. The risk of ovarian hyperstimulation syndrome (OHSS) for all cases was three times higher in the conventional follitropin alfa arm at 16.0% versus 5.1% with individualized follitropin delta treatment (P = 0.025) and 26.7% versus 7.7% (P = 0.001) for early moderate or severe OHSS, preventive interventions for early OHSS, or both. Conclusions: Treatment with individualized follitropin delta provides an improved efficacy-safety balance in women with high ovarian reserve, as it normalizes the ovarian response and decreases the risk of OHSS without compromising the chance of pregnancy.

Automated summary

Individualized follitropin delta dosing provides an improved efficacy-safety balance in women with high ovarian reserve, reducing the risk of ovarian hyperstimulation syndrome (OHSS) without compromising the chance of pregnancy.